Exclusive—Dr. Michael C. Burgess: We Need a New Playbook to Guard Against Counterfeit Drug Ingredients from China

Dr. Michael C. Burgess, a former congressman and physician, called for changes to U.S. pharmaceutical regulatory policy, specifically the "Green List" program that provides preferential treatment to certain foreign firms importing active pharmaceutical ingredients into the United States. Burgess stated the trust-based system requires updating to address counterfeit drug ingredients. The report he referenced recommends discontinuing the current Green List framework.

Next story